Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fludrocortisone
Drug ID BADD_D00917
Description Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency.[A5423]
Indications and Usage For partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.
Marketing Status Not Available
ATC Code H02AA02
DrugBank ID DB00687
KEGG ID D07967
MeSH ID D005438
PubChem ID 31378
TTD Drug ID D0R7JT
NDC Product Code Not Available
Synonyms Fludrocortisone | 9-Fluorocortisol | 9 Fluorocortisol | 9 alpha Fludrohydrocortisone | 9 alpha-Fluoro-17-Hydroxycorticosterone | 9 alpha Fluoro 17 Hydroxycorticosterone | 9-Fluoro-17-Hydroxycortisone | 9 Fluoro 17 Hydroxycortisone | 9-Fluorohydrocortisone | 9 Fluorohydrocortisone | 9 alpha-Fluorohydrocortisone | 9 alpha Fluorohydrocortisone | Astonin | Astonin-H | Astonin H | Astonin Merck | Merck, Astonin | FCOL
Chemical Information
Molecular Formula C21H29FO5
CAS Registry Number 127-31-1
SMILES CC12CCC(=O)C=C1CCC3C2(C(CC4(C3CCC4(C(=O)CO)O)C)O)F
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Alkalosis hypokalaemic14.01.02.002--Not Available
Amenorrhoea05.05.01.002; 21.01.02.001--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Anaphylactoid reaction10.01.07.003; 24.06.03.007--Not Available
Asthenia08.01.01.001--Not Available
Atrophy08.03.04.001--Not Available
Benign intracranial hypertension17.07.02.001--Not Available
Carbohydrate tolerance decreased13.02.02.003--Not Available
Cardiac failure congestive02.05.01.002--Not Available
Cardiomegaly02.04.02.001--Not Available
Cataract06.06.01.001--
Cataract subcapsular06.06.01.002--Not Available
Dermatitis acneiform23.02.01.004--
Dermatitis allergic10.01.03.014; 23.03.04.003--Not Available
Dermatitis atopic10.01.04.004; 23.03.04.016--Not Available
Diabetes mellitus05.06.01.001; 14.06.01.001--Not Available
Ecchymosis01.01.03.001; 23.06.01.001; 24.07.06.002--Not Available
Erythema23.03.06.001--Not Available
Exophthalmos05.02.02.002; 06.09.04.001--Not Available
Fluid retention14.05.06.002; 20.01.02.003--Not Available
Fracture12.04.02.001; 15.08.02.001--
Glaucoma06.03.01.002--
Glucose tolerance decreased13.02.02.004--Not Available
Glucose tolerance impaired05.06.02.001; 14.06.02.001--
Glycosuria20.02.01.005--
Haemoglobin13.01.05.018--Not Available
Headache17.14.01.001--
Hirsutism05.05.01.005; 23.02.04.001--
Hyperglycaemia05.06.02.002; 14.06.02.002--
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene